Cost-Effectiveness of Implementing a Home Blood Pressure Telemonitoring Program

Why It Matters

Despite modest blood pressure improvements, the program’s enrollment costs raise overall spending, challenging its scalability for health systems seeking cost‑effective hypertension management.

Key Takeaways

• Enrollment cost $113.35 per patient
• SBP reduced 1.42 mm Hg, DBP 1.58 mm Hg
• Virtual encounter costs rose $11.80, office visits fell $6.52
• ICER $81.67 per mm Hg SBP reduction
• Medication intensity increased modestly

Pulse Analysis

Home blood pressure telemonitoring has emerged as a cornerstone of modern hypertension care, leveraging smartphones and connected cuffs to bring measurements out of the clinic. Clinical trials have repeatedly shown that self‑measured BP, especially when paired with remote coaching, can produce sizable reductions in systolic pressure and improve medication adherence. However, translating these gains into routine practice often encounters hidden expenses, such as device procurement, staff time for enrollment, and the infrastructure needed to integrate data into electronic health records. Understanding the balance between clinical outcomes and financial outlays is essential for payers and providers alike.

The Kaiser Permanente Southern California analysis enrolled 3,067 adults, most of whom were non‑Hispanic Black, and compared participants who completed enrollment with those who abandoned the program. Average enrollment cost was $113.35 per patient, driven by a $80.85 device and shipping charge plus $32.50 staff time. While office‑visit costs fell $6.52 and BP‑clinic costs dropped $2.58, virtual encounter expenses rose $11.80, resulting in a net cost increase of roughly $2.70 per member. Blood pressure fell modestly—1.42 mm Hg systolic and 1.58 mm Hg diastolic—yielding an incremental cost‑effectiveness ratio of $81.67 per mm Hg systolic reduction, a figure comparable to earlier simulation studies but higher than some intensive telehealth trials.

From a health‑system perspective, the modest BP gains may not justify the enrollment outlay unless the program can be streamlined or extended to achieve larger reductions. Strategies such as bulk device purchasing, automated enrollment workflows, or targeting patients with uncontrolled hypertension could improve the cost‑effectiveness profile. Moreover, longer follow‑up may capture downstream savings from avoided cardiovascular events, which are not reflected in a 12‑month horizon. Policymakers and insurers should weigh these factors when designing reimbursement models for remote monitoring, ensuring that financial incentives align with measurable clinical improvements and sustainable operational costs.